Expression of SIP1 Protein Indicates Poor Prognosis in Throat Cancer
The expression of SIP1 protein in pharyngeal squamous cell carcinoma tumours often indicates an advanced tumour stage, a high risk of recurrence and a poor prognosis, says a news study.
The expression of SIP1 protein in pharyngeal squamous cell carcinoma tumours often indicates an advanced tumour stage, a high risk of recurrence and a poor prognosis, says a news study.
‘Pharyngeal cancer often is detected at later stages, and the outlook for these patients historically has been poor and endoscopic submucosal dissection (ESD) is a newer technique for removing lesions in the gastrointestinal tract.’
Tweet it Now
Pharyngeal cancer often is detected at later stages, and the outlook for these patients historically has been poor. But recent developments in gastrointestinal endoscopy have allowed for earlier diagnosis of these lesions. When the cancer has been detected earlier, surgery and chemotherapy traditionally have been used. But these treatments can have negative effects on the patient's quality of life, including cosmetic deformities and/or long-term difficulties with swallowing and speech. ESD has been used for some patients with early pharyngeal cancer, but no prospective trials had been reported prior to this study.
Between September 2010 and August 2014, 54 patients who were diagnosed with superficial pharyngeal cancer were studied. Their cancers ranged from stage 0 to stage 4. The researchers' goal was to find out whether a complete resection (removal) rate of 80 percent or higher could be achieved with ESD.
Many Throat Cancer Patients can Skip Neck Surgery, Says Study
Patients with human papillomavirus (HPV) positive oropharyngeal cancer see increased rates of complete response on a post-radiation neck dissection than those with HPV-negative oropharyngeal cancer.
Patients with human papillomavirus (HPV) positive oropharyngeal cancer see increased rates of complete response on a post-radiation neck dissection than those with HPV-negative oropharyngeal cancer.
Most adverse events were temporary, such as swelling of the site and difficulty swallowing. Three patients had emphysema related to deeper dissection of the muscle layer. No serious adverse events were reported. For all of the patients, swallowing, speech and airway function were preserved. The three-year overall survival rate was 97.7 percent, and the three-year recurrence-free survival rate was 98.1 percent.
Advertisement
Research Suggests Recurrent Mouth and Throat Cancers Less Deadly When Caused by Virus
New research suggests that people with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy are twice as likely to be alive two years later.
New research suggests that people with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy are twice as likely to be alive two years later.
Source-Eurekalert
Potential Drug Paves the Way for Biggest Breakthrough in Throat Cancer Treatment
The medication used to treat ovarian cancer was found to stop the growth of tumors in the throat and also increased the effectiveness of chemotherapy.
The medication used to treat ovarian cancer was found to stop the growth of tumors in the throat and also increased the effectiveness of chemotherapy.
